- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
8
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
8 companies
Johnson & Johnson
Market Cap: US$450.2b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$186.00
7D
-0.3%
1Y
17.8%
Merck
Market Cap: US$209.5b
Operates as a healthcare company worldwide.
MRK
US$84.39
7D
-2.5%
1Y
-16.2%
CureVac
Market Cap: US$1.2b
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$5.27
7D
-2.0%
1Y
84.3%
CytomX Therapeutics
Market Cap: US$674.5m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$4.21
7D
29.1%
1Y
321.0%
SIGA Technologies
Market Cap: US$582.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$8.43
7D
3.7%
1Y
9.2%
Puma Biotechnology
Market Cap: US$246.8m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$4.95
7D
-4.2%
1Y
61.6%
Abeona Therapeutics
Market Cap: US$233.8m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.36
7D
-12.6%
1Y
-30.6%
Coherus Oncology
Market Cap: US$180.2m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.57
7D
-9.5%
1Y
116.2%